Skip to main content

PsA/SpA

Thromboembolic Risk with Tofacitinib in RA, PsA and UC

Aug 06, 2020

An analysis of the tofacitinib (Xeljanz) drug development program in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis suggests a low level risk for venous (VTE) and arterial thromboembolism (ATE).  



In the last 2 years, observational data has

Read Article

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Jul 31, 2020

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

Jul 24, 2020

Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.

Read Article

Low Risk of COVID in Biologic Treated Rheum Patients

Jul 23, 2020

In an Annals of Rheumatic Disease report, Italian investigators performed consecutive testing for SARS-CoV-2 (IgM and IgG) between 25 March to 25 May 2020 and compared test results between rheumatic disease (RMD) patients and the general population. 



Their study included 295

Read Article

For TNF Response in RA, Weight Matters

Jul 22, 2020

Patients with rheumatoid arthritis (RA) who were obese were significantly less likely to remain on treatment with tumor necrosis factor (TNF) inhibitors -- but so were those who were underweight, a large, long-term study determined.

Compared with patients with normal weight, patients in obesity

Read Article

Risankizumab Outduels Secukinumab in Psoriasis

Jul 20, 2020

The IMMerge trial has demonstrated the superiority of interleukin (IL)‐23 over IL-17A inhibition adults with plaque psoriasis.



This multicenter, phase 3, open‐label study enrolled 327 adult patients with chronic, moderate‐to‐severe plaque psoriasis who were randomised risankizumab (

Read Article
RheumNow Podcast is Up! Listen to Fauci! Watch it here>> https://t.co/dHq3fP85Ip or Listen to the Podcast>> https://t.co/LdHO7fKUCp

Dr. John Cush RheumNow ( View Tweet)

Jul 17, 2020

RheumNow Podcast – LTF – Listen to Fauci (7.17.20)

Jul 17, 2020

Dr. Jack Cush reviews the news, tweets and journal articles from the past week on RheumNow. Let's dig into this week's 14 highlights.

Read Article
The preliminary #ACR20 schedule is here! Along with all your favorite plenary and networking sessions, the program will feature #Rheumatologist Dr. Anthony Fauci giving us a live update on #COVID19.

Victoria Shanmugam VickiShanmugam ( View Tweet)

Jul 16, 2020
FDA has approved guselkumab (Tremfya) for active psoriatic arthritis, making it the 1st IL-23 inhibitor approved for PsA. Approval is based on DISCOVER-1 & DISCOVER-2 RCTs. Dosing: 100 mg SC q8 wks after loading dose at 0, 4 wks. https://t.co/1nCWuC1zii

Dr. John Cush RheumNow ( View Tweet)

Jul 14, 2020

IL-17 Superior to TNF Inhibition in Psoriatic Arthritis

Jul 14, 2020

A one year head-to-head (H2H) trial has shown ixekizumab (IXE) to be superior to adalimumab (ADA) in psoriatic arthritis (PsA); for both skin and articular outcomes.

The SPIRIT H2H study was a 52-week trial of 566 biologic DMARD naive, PsA patients, randomized to received either IXE or ADA. The

Read Article
FDA has approved a 6th adalimumab biosimilar - called Hulio (adalimumab-fkjp) with indications of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, psoriasis.

Dr. John Cush RheumNow ( View Tweet)

Jul 13, 2020
African-Americans with Ank Spondylitis have worse disease compared to whites. Study of 10,990 AS patients shows AA to have high frequency of anterior uveitis, hypertension, diabetes, depression, and heart disease and higher ESR and CRP levels.

Dr. John Cush RheumNow ( View Tweet)

Jul 08, 2020
Rheumatology Round-Up from #EULAR2020 w/ Drs. Kavanaugh & Cush.

Dr. John Cush RheumNow ( View Tweet)

Jul 07, 2020
#EULAR2020 #op0106 Cosentyx 150mg demonstrates clinical improvement in NrAxSpA Sx in Ph3 PREVENT @52wk. Significant improvement in ASAS40, BASDAI50& ASdAS-CRP ID.
Dr. John Cush RheumNow ( View Tweet)
Jul 07, 2020

Liver Abnormalities in Psoriatic Arthritis

Jul 01, 2020

A new report in the Journal of Rheumatology shows that liver abnormalities are common in psoriatic arthritis (PsA) and may be associated with obesity, more severe disease and select therapies.



An analysis of a prospective PsA cohort study included 1061 patients. Of these, over one-

Read Article

Premature Atherosclerosis in Autoimmune Rheumatic Diseases

Jul 01, 2020

The VITAL study is a VA registry that has shown that both systemic lupus erythematosus  (SLE) and rheumatoid arthritis (RA) patients carry higher odds of both premature and extremely premature atherosclerotic cardiovascular disease and its consequences.

Read Article
CHMP of the EMA has recommended approval of intravenous & subcutaneous formulations of CT-P13 (Remsima) for use in 5 conditions - Crohn, UC, ankylosing spondylitis, PsA & psoriasis. Remsima dose is 120 mg q 2wks regardless of body weight.

Dr. John Cush RheumNow ( View Tweet)

Jun 30, 2020

Is IL-23 Better than IL-17 Inhibition in Psoriasis?

Jun 29, 2020

Data presented at the recent American Academy of Dermatology meeting suggests that interleukin (IL)-23 inhibition with risankizumab was more effective than the IL-17 inhibition (secukinumab) based on a 52 week randomized head-to-head trial in moderate to severe psoriasis patients.



The

Read Article
The CHMP of the European Medicines Agency has recommended the label expansion of IL-17 inhibitor, Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6-18 years. https://t.co/1qYL5ASkrg

Dr. John Cush RheumNow ( View Tweet)

Jun 29, 2020

RheumNow Podcast – Lupus Mortality Declines, But… (6.26.20)

Jun 26, 2020

Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article

Adverse Events With Rheum Biologics Rise With Age

Jun 23, 2020

Among patients with rheumatic diseases, age and female sex were important factors associated with the development of a first adverse event after initiating biologic treatment, Spanish researchers reported.

Read Article
WHO global safety database shows increased risk of DVT & PE with tofacitinib & baricitinib, who were likely to be older with preexisting VTE risk. In EU, TOFA risk for DVT/PE was OR 2.3; BARI risk was OR 3.4.

Dr. John Cush RheumNow ( View Tweet)

Jun 22, 2020
#EULAR2020 Round-Up w/ Drs. Kavanaugh & Cush.

Dr. John Cush RheumNow ( View Tweet)

Jun 21, 2020
RheumNow Podcast is Up! New FDA approvals for secuminumab, canakinumab, risk of GI perforations, tocilizumab in COVID, Weaning DMARDs/Biologics and Blacks with AS.

Dr. John Cush RheumNow ( View Tweet)

Jun 20, 2020
×